World Federation of Societies of Biological Psychiatry (WFSBP) consensus statement on candidate biomarkers for anorexia nervosa.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Himmerich Hubertus, Keeler Johanna Louise, King Joseph A, Ehrlich Stefan, Kaufmann Lisa-Katrin, Bulik Cynthia M, Cohen-Woods Sarah, Wade Tracey, Steiger Howard, Booij Linda, Monteleone Palmiero, Cascino Giammarco, Monteleone Alessio Maria, Cuntz Ulrich, Voderholzer Ulrich, Tessema Selamawit Alemayehu, Lewis Yael D, Sjögren Magnus, Hebebrand Johannes, Seitz Jochen, Tyszkiewicz-Nwafor Marta, Karpenko Olga, Mutwalli Hiba, Fetissov Sergueï O, Mack Isabelle, Dhopatkar Namrata, Mörkl Sabrina, Kan Carol, Uribe Maria M, Yoshiuchi Kazuhiro, Abuobeid Nadine, Kapogiannis Dimitrios, Stein Daniel, Bektas Sevgi, Müller Daniel J, Gorwood Philip, Duriez Philibert, Montcel Chloé Tezenas du, Paszyńska Elżbieta, McElroy Susan L, Wranik Wiesława Dominika, Fernandez-Aranda Fernando, Mehler Philip S, Papežová Hana, Roubalová Radka, Procházková Petra, Morris Rebecca, Lewczuk Piotr, Hiemke Christoph, Berk Michael, Karwautz Andreas, Treasure Janet, Kasper Siegfried, WFSBP Task Force on Biological Markers, WFSBP Task Force on Eating Disorders
Аннотация
METHODS: The relevant literature was reviewed by the WFSBP Task Forces on Eating Disorders and on Biological Markers, and a consensus regarding the significance of the published evidence was reached.
RESULTS: Candidate biological markers that have been associated with AN include clinical (e.g. body weight), molecular (e.g. genetic, epigenetic, hormonal, immunological, metabolomic), cellular (e.g. leukocytes), neuroimaging (e.g. structure, function, connectivity), digital, cardiac and neurophysiological parameters. Some clinical and laboratory parameters are risk markers in clinical practice. Biological markers have pathophysiological relevance in understanding the biological and metabolic pathophysiology of AN and its physical health consequences. Few studies have examined pharmacogenetics or therapeutic drug monitoring as tools to monitor and guide the treatment of AN.
CONCLUSIONS: Biological markers will hopefully soon enable clinicians to intervene earlier in a more targeted manner to mitigate treatment resistance. However, the current scientific basis for most biological markers are group comparisons only. Studies on sensitivity, specificity and the prognostic value of these markers are lacking.